Lantern Pharma Inc
NASDAQ:LTRN

  • LAST PRICE
    3.2550
  • TODAY'S CHANGE (%)
    0.1450 (4.6624%)
  • Bid / Lots
    3.1200/ 1
  • Ask / Lots
    3.6000/ 2
  • Open / Previous Close
    3.1400 / 3.1100
  • Day Range
    3.1400
    3.3889
  • 52 Week Range
    2.7900
    11.9900
  • Volume
    13,332

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

Charts

Price Comparison Graph. See accessible table below
Data delayed at least 15 minutes.

Biotechnology Industry Peers

CompanyMarket CapP/E Ratio (TTM)EPS Growth (5yr)
LTRN
Lantern Pharma Inc
33.5M
-1.8x
---
CMMB
Chemomab Therapeutics Ltd
33.6M
-1.9x
---
SRZN
Surrozen Inc
33.2M
-0.7x
---
GRCE
Grace Therapeutics, Inc
34.2M
-3.1x
---
NXTC
NextCure Inc
32.8M
-0.6x
---
LIANY
LianBio
32.0M
-0.4x
---
As of 2024-11-30

Company Information

Lantern Pharma Inc. is an artificial intelligence (AI) company. The Company is developing targeted and transformative cancer therapies using its proprietary RADR AI and machine learning (ML) platform with multiple clinical-stage drug programs. Its proprietary AI and machine learning (ML) platform, RADR, leverages over 60 billion oncology-focused data points and a library of over 200 advanced ML algorithms to help solve problems in oncology drug development. It is engaged in the development of its pipeline of therapies that span multiple cancer indications, including both solid tumors and blood cancers and an antibody drug conjugate (ADC) program. It has active clinical programs for its three lead small molecule drug candidates: LP-300, LP-184, and LP-284. These programs are focused on multiple cancer indications, including both solid tumors and blood cancers. It is also focused on the clinical execution of its therapies for CNS and brain cancers through Starlight Therapeutics Inc.

Contact Information

Headquarters
1920 MCKINNEY AVENUE, 7TH FLOORDALLAS, TX, United States 75201
Phone
972-277-1136
Fax
302-655-5049

Executives

Independent Chairman of the Board
Donald Keyser
President, Chief Executive Officer, Director
Panna Sharma
Chief Financial Officer, Secretary
David Margrave
Chief Scientific Officer
Kishor Bhatia
Chief Medical Officer
Marc Chamberlain

Ratings

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

Reports

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals

Market Cap
$33.5M
Revenue (TTM)
$0.00
Shares Outstanding
10.8M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.56
EPS
$-1.77
Book Value
$3.82
P/E Ratio
-1.8x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Calendar

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.